FDA: New Real-Time Dashboard for Reporting Adverse Effects in Cosmetics

The U.S. Food and Drug Administration (FDA) has introduced a new public tool: a real-time dashboard for viewing adverse event reports related to cosmetic products. This panel—called the FAERS Public Dashboard for Cosmetic Products—updates data daily and allows users to view adverse event reports for products such as creams, shampoos, hair dyes, and tattoos.

Table of contents

1. More transparency and public access

2. What kind of data does it contain?

3. Regulatory and industry importance

4. Conclusion

FDA: New Real-Time Dashboard for Reporting Adverse Effects in Cosmetics

More transparency and public access

With this launch (September 12, 2025), the FDA strengthens its strategy of radical transparency in public health matters. Anyone can now search and download data from recent reports, filtering by product, type of event, or severity.

FDA Commissioner Marty Makary noted that citizens “deserve greater understanding about the safety of the cosmetics they use every day,” and that this dashboard is a way for the public to help identify potential signs of risk.

What kind of data does it contain?

The dashboard includes both mandatory reports—submitted by “responsible persons” under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) —and voluntary reports from healthcare professionals, consumers, aestheticians, salons, and more.

Some key features:

• Entries can be filtered by product, type of adverse event, date, or severity level.

• The data have not been verified by the FDA ; publication does not imply that the product caused the effect.

• The dashboard should not be interpreted as an absolute indicator of safety, but rather as a source of preliminary signals.

Regulatory and industry importance

This step represents a reinforcement of post-market surveillance in cosmetics. For manufacturers and distributors, it represents an increase in responsibility: reports received by the system could draw attention to specific products.

For consumers and professionals, it's a powerful tool: they'll be able to examine potential problems with cosmetic products firsthand, boosting industry accountability.

Conclusion

The FDA's creation of this dashboard symbolizes a shift toward more active and participatory oversight of cosmetic safety. Although it is not a definitive risk assessment, it provides public visibility into reported effects and can serve as a warning to manufacturers, regulators, and consumers.

Contact an expert in international cosmetics regulation.